DRESIS: the first comprehensive landscape of drug resistance information
Nucleic Acids Research · 06.01.2023 · 51 (D1) · D1263-D1275
DOI: 10.1093/nar/gkac812 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, online erschienen am 16.10.2022. Verfasst von Xiuna Sun und 13 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmaceutical Sciences, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou 310058, Chi…. Hauptthemen laut MEDLINE: Drug Discovery. Die Arbeit wurde bisher 72-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Natural Science Foundation of Zhejiang Province, National Natural Science Foundation of China, National High-Level Talents Special Support Plan of China.
Abstract (Originalsprache)
Widespread drug resistance has become the key issue in global healthcare. Extensive efforts have been made to reveal not only diverse diseases experiencing drug resistance, but also the six distinct types of molecular mechanisms underlying this resistance. A database that describes a comprehensive list of diseases with drug resistance (not just cancers/infections) and all types of resistance mechanisms is now urgently needed. However, no such database has been available to date. In this study, a comprehensive database describing drug resistance information named ‘DRESIS’ was therefore developed. It was introduced to (i) systematically provide, for the first time, all existing types of molecular mechanisms underlying drug resistance, (ii) extensively cover the widest range of diseases among all existing databases and (iii) explicitly describe the clinically/experimentally verified resistance data for the largest number of drugs. Since drug resistance has become an ever-increasing clinical issue, DRESIS is expected to have great implications for future new drug discovery and clinical treatment optimization. It is now publicly accessible without any login requirement at: https://idrblab.org/dresis/
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- College of Pharmaceutical Sciences, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou 310058, China.
- Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, Alibaba-Zhejiang University Joint Research Center of Future Digital Healthcare, Hangzhou 330110, China.
- The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou 310058, China.
- Zhejiang University-University of Edinburgh Institute, Zhejiang University, Haining 314499, China.
ORCID-Profile: Hanyu Zhang, Minjie Mou, Feng Zhu
Förderung
- Natural Science Foundation of Zhejiang Province
- National Natural Science Foundation of China
- National High-Level Talents Special Support Plan of China
- Fundamental Research Fund of Central University
- Key R&D Program of Zhejiang Province
- Chinese ‘Double Top-Class’ Universities
- Westlake Laboratory
- Alibaba-Zhejiang University
Zitieren
APA
Sun, X., Zhang, Y., Li, H., Zhou, Y., Shi, S., Chen, Z., He, X., Zhang, H., Li, F., Yin, J., Mou, M., Wang, Y., Qiu, Y., & Zhu, F. (2023). DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Research, 51(D1), D1263-D1275. https://doi.org/10.1093/nar/gkac812
Vancouver
Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, et al. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Research. 2023;51(D1):D1263-D1275. doi:10.1093/nar/gkac812
BibTeX
@article{Sun2023,
author = {Sun, Xiuna and Zhang, Yintao and Li, Hanyang and Zhou, Ying and Shi, Shuiyang and Chen, Zhen and He, Xin and Zhang, Hanyu and Li, Fengcheng and Yin, Jiayi and Mou, Minjie and Wang, Yunzhu and Qiu, Yunqing and Zhu, Feng},
title = {DRESIS: the first comprehensive landscape of drug resistance information},
journal = {Nucleic Acids Research},
year = {2023},
volume = {51},
number = {D1},
pages = {D1263--D1275},
doi = {10.1093/nar/gkac812}
}
EUVIMED